Clinical Trial Update: Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients [Phase 4]

View source ↗

Summary

A Phase 4 safety study evaluating SMOFlipid for risk of essential fatty acid deficiency and parenteral nutrition-associated cholestasis in children and adults. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Fatty Acid Deficiency
• Malnutrition
• Parenteral Nutrition Associated Cholestasis

Drugs mentioned

• SMOFLIPID

Snippet

Sponsor: Fresenius Kabi | Conditions: Malnutrition, Child, Malnutrition | Phase 4 | Status: RECRUITING